| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 74.77B | 73.25B | 63.12B | 65.08B | 62.67B | 59.14B |
| Gross Profit | 19.24B | 18.24B | 13.15B | 12.96B | 15.72B | 15.18B |
| EBITDA | 9.10B | 8.68B | 5.85B | 3.83B | 7.98B | 7.46B |
| Net Income | 2.96B | 2.58B | 1.17B | -407.00M | 2.49B | 2.56B |
Balance Sheet | ||||||
| Total Assets | 94.19B | 97.11B | 94.54B | 85.03B | 86.47B | 85.03B |
| Cash, Cash Equivalents and Short-Term Investments | 15.44B | 16.75B | 16.13B | 9.13B | 12.22B | 11.60B |
| Total Debt | 30.52B | 31.35B | 35.14B | 32.47B | 30.87B | 32.10B |
| Total Liabilities | 50.29B | 52.60B | 53.24B | 46.73B | 46.09B | 47.63B |
| Stockholders Equity | 38.95B | 38.73B | 36.75B | 34.35B | 36.77B | 34.65B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 5.39B | 4.59B | -2.11B | 2.86B | 557.00M |
| Operating Cash Flow | 0.00 | 7.53B | 7.09B | 724.00M | 5.52B | 4.96B |
| Investing Cash Flow | 0.00 | -2.14B | -2.01B | -2.88B | -2.70B | -3.80B |
| Financing Cash Flow | 0.00 | -5.04B | 1.65B | -1.03B | -2.34B | 255.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥33.57B | 12.50 | ― | 1.90% | 2.15% | 16.14% | |
75 Outperform | ¥89.30B | 30.30 | ― | 1.12% | 3.77% | 7.65% | |
74 Outperform | ¥38.98B | 4.82 | ― | 3.70% | 14.83% | 51.42% | |
70 Outperform | ¥51.37B | 21.73 | ― | 3.77% | 8.54% | 6.93% | |
68 Neutral | ¥108.46B | 21.28 | ― | 1.24% | 8.78% | 19.37% | |
65 Neutral | ¥37.20B | 19.44 | ― | 2.37% | -11.70% | -54.82% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
DKS Co., Ltd. announced it has corrected previously released consolidated financial results for the six months ended September 30, 2025, after discovering errors in its dividend disclosure. The corrections revise the fiscal years associated with stated cash dividends per share, clarifying that the previously disclosed dividend figures and forecasts apply to the fiscal years ended and ending March 31, 2025 and March 31, 2026, rather than 2024 and 2025 as initially reported; the dividend amounts themselves, including the forecast of a total annual dividend of ¥140.00 for the year ending March 31, 2026, remain unchanged, limiting the impact to a clarification of timing rather than a change in shareholder returns.
The most recent analyst rating on (JP:4461) stock is a Buy with a Yen10046.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.
DKS Co., Ltd. has raised its consolidated forecast for the fiscal year ending March 31, 2026, projecting higher net sales and profits than previously expected, with all earnings indicators now set to exceed record levels achieved in the prior year. The upgrade reflects robust third‑quarter performance and sustained strong demand for low‑dielectric resins in high‑end servers and water‑based composite adhesives for battery negative electrodes, which are driving both top‑line growth and profitability. In line with these improved results and faster‑than‑planned progress on its mid‑term management plan “SMART 2030,” the company also increased its year‑end dividend forecast from ¥80 to ¥90 per share, lifting the expected annual dividend to ¥150 per share and signaling enhanced shareholder returns supported by stronger earnings momentum.
The most recent analyst rating on (JP:4461) stock is a Buy with a Yen10046.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.
DKS Co., Ltd. reported strong consolidated results for the nine months ended December 31, 2025, with net sales up 10.9% year on year to ¥60.2 billion and profit attributable to owners of parent more than doubling to ¥4.2 billion, reflecting significant margin improvement and robust growth in comprehensive income. The company also strengthened its financial position, with total assets and equity rising and the equity ratio improving to 44.3%, and it raised both its full-year earnings and dividend forecasts for the fiscal year ending March 31, 2026, signaling confidence in sustained profit growth and a higher shareholder return policy.
The most recent analyst rating on (JP:4461) stock is a Buy with a Yen10046.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.
DKS Co., Ltd. has completed the payment procedures for the disposal of treasury stock under its Employee Shareholding Association-Restricted Stock Incentive Plan. The number of shares to be disposed of was adjusted due to partial forfeiture, resulting in a disposal of 29,641 shares instead of the initially planned 31,857 shares, reflecting changes in the number of consenting members.
The most recent analyst rating on (JP:4461) stock is a Buy with a Yen8490.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.
DKS Co. Ltd. and D. Western Therapeutics Institute, Inc. have announced positive results from their joint research project aimed at developing a treatment for dry eye. The collaboration, which began in December 2024, has confirmed the pharmacological effects of a synthesized compound in animal models, leading to an extension of their research agreement. This project is part of DKS’s efforts in its Life & Wellness segment to enhance research and development in the pharmaceutical field, with the goal of improving quality of life in an aging society. The joint research results will not impact the earnings forecast for the fiscal year ending March 2026.
The most recent analyst rating on (JP:4461) stock is a Buy with a Yen6677.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.
DKS Co., Ltd. has initiated a joint research project with Kyoto University to develop new drugs for neurodegenerative diseases, such as Parkinson’s and Alzheimer’s. This collaboration aims to evaluate the efficacy of DKS’s compounds and understand their mechanisms of action, with the goal of providing alternative treatments to existing symptomatic therapies. The research will utilize the Share Lab EVER SHIMOGAMO facility to enhance testing capabilities and foster collaboration with experts, thereby potentially improving the quality of life for patients.
The most recent analyst rating on (JP:4461) stock is a Buy with a Yen6677.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.
DKS Co., Ltd. has revised its financial and dividend forecasts for the fiscal year ending March 31, 2026, due to strong performance in its Electronics & IT and Environment & Energy segments. The company expects record-high profits, surpassing previous forecasts and targets set in its mid-term management plan ‘SMART 2030.’ Consequently, the annual dividend per share is projected to increase, reflecting the company’s commitment to stable shareholder returns.
The most recent analyst rating on (JP:4461) stock is a Buy with a Yen6677.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.
DKS Co., Ltd. reported strong financial results for the six months ending September 30, 2025, with a notable increase in net sales and profits compared to the previous year. The company revised its earnings and dividend forecasts upwards, indicating confidence in its continued growth and stability, which is likely to positively impact stakeholders and enhance its industry positioning.
The most recent analyst rating on (JP:4461) stock is a Buy with a Yen6677.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.